Leeds Melanoma Cohort and the BioGenoMEL Consortium

The information on this page is archived and provided for reference purposes only.

Contact: Julia Newton-Bishop, M.D.

Study Website: http://www.biogenomel.euExternal Web Site Policy

Number of Enrolled Cancer Patients/Survivors: The Leeds Cohort has 2,005 melanoma patients ascertained from a defined geographical area. The BioGenoMEL Consortium has 11 additional cohorts from the United States and Europe.
Years of Diagnoses of Enrolled Cancer Patients/Survivors: Recruitment began in 2000 for the Leeds Cohorot and is still ongoing.
Cancer Sites Represented: Melanoma Only
Biological Specimens Collected: Blood/Blood Fraction (Serum & plasma and frozen lymphocytes from the Leeds Melanoma Cohort)
Germline DNA (the Leeds Melanoma Cohort and BioGenoMEL cohorts)
Formalin Fixed Tumor Tissue
Treatment Outcome Measures: Physician/Medical Record Reported
  • Acute Medical Event
  • Late Medical Event
  • Cancer Recurrence
  • Death
Patient-Reported
  • Acute Medical Event
  • Late Medical Event
  • Quality of Life
  • Cancer Recurrence
  • Detailed Environmental Exposure Questionnaire (e.g., diet supplementation)
Co-morbidities at Study Entry: Diabetes
Heart Disease
Pulmonary Disease
General Medical History
Lifestyle Factors: Smoking
Alcohol Use
Diet (not very detailed)
Physical Activity
Body Mass Index
Treatment Data: Surgery
Radiation
Chemotherapy
Treatment Data Assessed By: Electronic Record (where available)
Chart Abstraction
Patient Reported Questionnaire
Is the study open to collaboration? Yes

Return to Top

The information on this page is archived and provided for reference purposes only.